Synthetic Oligonucleotides: The Development of Antisense Therapeutics

Nucleic Acid Therapeutics: Current Targets For Antisense Oligonucleotides And Ribozymes

Nucleic acids are becoming increasingly important as therapeutic molecules mainly for the ease with which specificity for a vast range of targets of these drugs is achieved. Yet the dose rates of several mg/kg are not easy to provide. Reform of drug policy has been suggested earlier to facilitate newer therapeutic strategies to be put to use. With the current technology, each mg of the unmodifi...

Antisense antivirals: future oligonucleotides-based therapeutics for viral infectious diseases

Despite the availability of antiviral chemotherapies, human pathogenic viral infections remain a global health problem, causing formidable morbidity and mortality worldwide. Of particular concern are those virus types developing (multi)drug-resistance, eg. herpesviruses, hepatitis C virus (HCV), and human immunodeficiency virus (HIV), that fail almost all the available antiviral drugs in clinic...

Development of Synthetic Lethality Anticancer Therapeutics

The concept of synthetic lethality (the creation of a lethal phenotype from the combined effects of mutations in two or more genes) has recently been exploited in various efforts to develop new genotype-selective anticancer therapeutics. These efforts include screening for novel anticancer agents, identifying novel therapeutic targets, characterizing mechanisms of resistance to targeted therapy...

Designing Antisense Oligonucleotides

Antisense Oligonucleotides Targeting Protein